| 2017 A/H7N9 IIV Revaccination (NCT03738241) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-12-18 |
| Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza (NCT03682120) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-11-02 |
| H5N1 With or Without Topical Aldara in Healthy Adults (NCT03472976) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-06-13 |
| Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 (NCT03318315) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-20 |
| Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly (NCT03312231) | National Institute of Allergy and Infectious Diseases (NIAID) | 2018-02-14 |
| A Safety and Immunogenicity Study of IVACFLU-A/H5N1 (NCT02612909) | Institute of Vaccines and Medical Biologicals, Vietnam | 2017-03-07 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology (NCT03014310) | National Institute of Allergy and Infectious Diseases (NIAID) | 2017-01-09 |
| H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses (NCT02921997) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-11-07 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults (NCT02624219) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-16 |
| A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age (NCT02839330) | Seqirus | 2016-07-11 |
| A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine (NCT02251288) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-05-18 |
| H7N9 Mix and Match With MF59 in Healthy Elderly Persons (NCT02213354) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-10-01 |
| Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine (NCT02229357) | Mahidol University | 2014-06-01 |
| A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 (NCT01897701) | Novavax | 2013-07-01 |
| Safety and Pharmacokinetics Study of FBF001 (NCT02295813) | Fab'entech | 2012-10-01 |
| A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine (NCT01675284) | Medigen Biotechnology Corporation | 2012-08-01 |
| Studies of Avian Influenza Transmission to Humans in Egypt (NCT01150552) | St. Jude Children's Research Hospital | 2010-06-01 |
| Avian Influenza Studies In Lebanon (NCT01107262) | St. Jude Children's Research Hospital | 2009-07-01 |
| Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine (NCT00561184) | Novartis Vaccines | 2007-10-01 |
| Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects (NCT00481065) | Novartis | 2007-04-01 |
| High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza (NCT00298233) | National Institute of Allergy and Infectious Diseases (NIAID) | 2006-02-01 |